| Variables | Effect on recurrent hepatitis C |
| Donor and graft factors | | Age [17, 37–43] | More severe disease (>40, >50, >65) | Steatosis [56, 57, 76–79] | Few studies | Prolonged ischemic time [54, 55, 80–83] | More severe disease | HCV+ graft [6, 22, 40, 50–53, 76] | No influence | Reduced size versus whole liver (LDLT versus DDLT) [39, 84–95] | No difference | Pretransplant recipient factors | | Genotype 1b [8, 32, 33, 35, 40] | Controversial | Pre-LT higher viral load [21, 28, 96, 97] | Unclear | Age [32, 44, 98] | Few studies | Race [45, 46, 99] | Few studies | Sex [20, 47, 48] | Few studies | HIV coinfection [100–107] | No influence | IL-28B gene polymorphism [49, 108–111] | More severe disease in CT and TT genotype | Posttransplant recipient factors | | Post-LT higher viral load [10, 27–31] | More severe disease | CMV infection [22, 29, 32, 112–116] | Unclear | Diabetes mellitus (Metabolic syndrome) [29, 117–121] | More severe disease | Immunosuppression | | Steroid bolus/OKT3 [6, 21, 22, 58, 59, 122–124] | More severe disease | Maintenance steroid [34, 60–62, 122] | Severe disease when rapidly tapered | Steroid free regimen [63–68, 125–127] | No influence | Tacrolimus versus cyclosporine [69–75] | No difference | Anti-IL-2 receptor antibodies [63, 126, 128–131] | Controversial | Azathioprine/mycophenolate mofetil [132–140] | Controversial | mTOR inhibitors [141–143] | Few studies |
|
|